Market revenue in 2023 | USD 2,052.9 million |
Market revenue in 2030 | USD 5,739.9 million |
Growth rate | 15.8% (CAGR from 2023 to 2030) |
Largest segment | Functional genomics |
Fastest growing segment | Pathway Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery |
Key market players worldwide | Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Eppendorf, Eurofins Scientific SE, Roche Holding AG ADR, GE Aerospace, Illumina Inc, Myriad Genetics Inc, Oxford Nanopore Technologies PLC, Pacific Biosciences of California Inc, Qiagen NV, Quest Diagnostics Inc, Thermo Fisher Scientific Inc, 23andMe Holding Co Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to genomics market will help companies and investors design strategic landscapes.
Functional genomics was the largest segment with a revenue share of 31.69% in 2023. Horizon Databook has segmented the Spain genomics market based on functional genomics, epigenomics, pathway analysis, biomarker discovery covering the revenue growth of each sub-segment from 2018 to 2030.
Over time, Spain has become a competitive and attractive market for genomics. In September 2020, the Spanish government allocated USD 29.5 million for genomic & precision medicine and data science. This investment aimed to increase the capability of the regional health system and usage scientific knowledge as a tool to hold economic attractiveness by contributing to innovation.
The segment of investment included genomic medicine, predictive medicine, big data health, precision medicine training and advanced & personalized therapy. This government initiative was expected to strengthen the position of existing players as well as attract new startups.
EASI-Genomics is headquartered in Spain and operates via collaborations with various key genome centers in the European region to facilitate access to novel technologies pertaining to DNA sequencing. These collaborations are also expected to operate within a framework that enables compliance with both legal and ethical requirements while ensuring secure & safe data management.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain genomics market , including forecasts for subscribers. This country databook contains high-level insights into Spain genomics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account